Definium Therapeutics to present Phase 3 topline data for DT120 in MDD, GAD at Psych Congress 2026

PUBT · 2d ago
Definium Therapeutics to present Phase 3 topline data for DT120 in MDD, GAD at Psych Congress 2026
  • Definium Therapeutics scheduled topline Phase 3 results for DT120 in major depressive disorder, generalized anxiety disorder at Psych Congress 2026.
  • Data will be presented September 17-19 in New Orleans, including an invited oral session on emerging trends in depression.
  • The readouts are positioned to support DT120’s broader late-stage profile across two large psychiatric markets, alongside additional safety analyses.
  • Separate posters will outline epidemiological findings on suicidal ideation risk across anxiety, depression, comorbid populations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609100700BIZWIRE_USPR_____20260908_BW936040) on September 10, 2026, and is solely responsible for the information contained therein.